Brief: Sedana Medical Gets Data Exclusivity, Market Protection For Sedaconda Until 2031
Nov 22 (Reuters) - Sedana Medical AB (publ) SEDANA.ST :
* GETS DATA EXCLUSIVITY AND MARKET PROTECTION FOR
SEDACONDA ®
(ISOFLURANE) UNTIL 2031
* EUROPEAN MEDICINES AGENCY'S (EMA) PAEDIATRIC COMMITTEE HAS
GIVEN
A POSITIVE DECISION REGARDING COMPLIANCE WITH THE COMPANY'S
PEDIATRIC INVESTIGATION PLAN
Source text for Eikon: ID:nWkrtbHrw
Further company coverage: SEDANA.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Sedana Medical AB (publ)
See all newsSweden's Sedana Medical Q3 sales rise as growth returns
Brief: Sedana Medical Announces PDUFA Target Action Date
Brief: Sedana Medical Announces FDA Acceptance For Review Of Its New Drug Application In U.S.
Sweden's Sedana Medical Q2 sales flat, EBITDA loss narrows
Brief: Sedana Medical Q2 EBITDA Loss Narrows To SEK 1.9 Mln